Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Vivos Therapeutics" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Vivos Therapeutics for you to read. Along with our medical data and news we also list Vivos Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Vivos Therapeutics Companies for you to search.
Gotham Therapeutics Corp. (treatments for autoimmune and neurodegenerative diseases and cancer) raised $54mm through its Seri...
United Therapeutics (Nasdaq: UTHR) and MannKind (Nasdaq: MNKD) announced the closing of their pending worldwide exclusive license and collaboration agreement for the development and commercialization of Treprostinil Technosphere, a dry powder formulation of treprostinil being developed for the treatment of pulmonary arterial hypertension. As quoted in the press release: As previously announced, th...
Today's Daily Dose brings you news about FDA staffers' comments on AcelRx Pharma's pain drug candidate Dsuvia; Audentes Therapeutics' stock offering; FDA lifting clinical hold on CRISPR Therapeutics' investigational drug; TearLab's disappointment, and Trevena's much-awaited regulatory catalyst.
Emerging Company Profile: CoA Therapeutics plans to start a Phase I study of a CoA modulator in the rare, genetic...
Roche acquires Tusk Therapeutics of the UK for its lead asset; its other activities will continue as Black Belt Therapeutics...
G1 Therapeutics Inc. netted $170mm through the public sale of 3mm common shares at $60. The company develops drugs for cancer...
IFM Therapeutics is launching its second subsidiary in less than a year. This morning, the Boston-based company, launched IFM Due (pronounced du-way), a subsidiary company developing a suite of cGAS inhibitors and STING antagonists that can target diseases like NASH, lupus and Parkinson’s.
Bone Therapeutics is a biotechnology company with a unique approach to the development of cell therapy products for bone fracture repair and fracture prevention. Bone Therapeutics is creating a new and unique treatment approach using differentiated bone-forming cells administered via a minimally invasive percutaneous procedure, that is expected to offer significant benefits over the current stand...
CAMBRIDGE, Mass., March 05, 2019 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has priced an underwritten public offering of an aggregate of 2,604,167 shares of its common … Continue reading →
Sangamo Therapeutics, Inc. has announced the completion of the acquisition of TxCell, SA. TxCell is now a subsidiary of Sangamo and has been delisted from the French stock market.
Abeona Therapeutics (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced key pipeline updates during the Company’s 2018 R&D Day. As quoted in the press release: “The important clinical and preclinical updates we shared today further establish Abeona’s pathway to br...
Expanding its wound healing and tissue repair portfolio, Smith & Nephew PLC is paying $19 per share in cash (a 7% premium bas...
The German group believes it is going to be at the forefront of development in the cell and gene therapy...
Gyroscope Therapeutics has announced that the first patient has been dosed in its Phase I/II FOCUS study for dry age-related macular degeneration (AMD).
Simon Kerry the CEO of the Oxfordshire based company Karus Therapeutics, talks with Fintan Walton about the company's work to develop innovative medicines for the treatment of inflammatory disease and cancer.
Spark Therapeutics (NASDAQ:ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced findings from three post-hoc analyses of data from the Phase 3 clinical trial of LUXTURNA (voretigene neparvovec-rzyl) at the American Academy of Ophthalmology Annual Meeting in Chicago. As quoted in the press release: LUXTURNA is R...
10 RNA Therapeutics Companies To Watch In 2019 http://www.rttnews.com/slideshow/3798/rna-therapeutics-silencing-genes-cancer-tegsedi-onpattro-rnai-nafld-nash-beta-thalassaemia.aspx …
Agile Therapeutics Inc (NASDAQ:AGRX) CEO Al Altomari sat down with Proactive Investors at the BIO CEO and Investor Conference in New York. Agile's product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method.
Allergy Therapeutics PLC's (LON:AGY) CEO Manuel Llobet and chief financial officer Nick Wykeman discuss with Proactive London's Andrew Scott the group's results for the six months to December 2018. The company saw turnover rise 10.6% to £46.7mln in the period, up from £42.2mln a year earlier. 2019 is Allergy's 20th anniversary since they spun out of GlaxoSmithKline.
Nearly four years after investors snapped up new shares of Juno Therapeutics in a $265 million IPO, cancer immunotherapy remains a hot ticket. Like Juno, Allogene Therapeutics just pulled in a massive IPO haul, nearly $300 million. And like Juno, Allogene is working with a live immune-cell treatment called CAR-T, but it is harvesting cells […]
Acorda Therapeutics’ week started off badly and has only gotten worse. It started off with the loss of an appeal for some of its Ampyra patents and has ended with the U.S. FDA's decision to delay a ruling for its Parkinson’s disease treatment.
A potential rival for Allergan Plc's blockbuster Botox has passed a late-stage study, putting drug developer Revance Therapeutics Inc on course to file for U.S. marketing approval next year.
In our Emerald Health Therapeutics stock forecast 2019 we tipped this cannabis stock as a great buy opportunity for 2019. However, its price has been falling recently. There is even more downside a...
SAN FRANCISCO, Nov. 9, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today a presentation of new clinical and preclinical data for its I-O pipeline Read more...
New York (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse der Analysin Alethia Young von Cantor Fitzgerald: Analyst Alethia Young vom Investmenthaus Cantor Fitzgerald bestätigt laut einer ...